

Balance Sheet

as at March 31, 2024

₹ in Million			
Particulars	Notes	As at March 31, 2024	As at March 31, 2023
ASSETS			
(1) Non-current assets			
(a) Property, plant and equipment	3A (I) & (II)	101,923.2	103,903.8
(b) Building	3D	11,077.3	9,633.5
(c) Goodwill	47	85,989.5	83,580.3
(d) Patents for drugs and formulations	3B	33,201.1	33,170.3
(e) Intangible assets under development (R&D)	3E	64,461.5	60,098.1
(f) Investment in associates	4	4,061.3	3,474.8
(g) Investment in joint venture	5	364.8	361.6
(h) Financial assets			
(i) Investments	6	59,986.2	50,680.9
(ii) Loans	7	8.5	6.1
(iii) Other financial assets	8	1,179.5	1,710.4
(i) Deferred tax assets (Net)	50	41,036.5	35,189.2
(j) Income tax assets (Net)	9	22,850.3	23,069.8
(k) Other non-current assets	10	4,739.3	3,723.7
Total non-current assets		419,879.0	408,602.5
(2) Current assets			
(a) Inventories	11	98,682.9	105,130.5
(b) Financial assets			
(i) Investments	12	85,845.4	93,726.1
(ii) Trade receivables	13	112,493.7	114,385.1
(iii) Cash and cash equivalents	14	92,856.5	46,237.3
(iv) Bank balances other than (iii) above	15	12,350.3	11,465.6
(v) Loans	16	650.2	413.2
(vi) Other financial assets	17	9,172.0	7,645.1
(c) Other current assets	18	22,280.1	19,616.5
Total current assets		434,331.1	398,619.4
Assets classified as held for sale	3C	418.7	214.0
TOTAL ASSETS		865,628.8	807,435.9

Balance Sheet

as at March 31, 2024

₹ in Million			
Particulars	Notes	As at March 31, 2024	As at March 31, 2023
EQUITY AND LIABILITIES			
Equity			
(a) Equity share capital	19	2,399.3	2,399.3
(b) Other equity	20	634,268.2	557,554.5
Equity attributable to the equity shareholders of the parent company		636,667.5	559,953.8
Non-controlling interests	71	34,392.2	33,200.9
Total equity		671,059.7	593,154.7
Liabilities			
(1) Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	21	13.3	-
(ii) Lease liabilities	54	3,022.9	5,599.1
(iii) Other financial liabilities	22	-	37.9
(b) Provisions	23	4,138.9	3,429.1
(c) Deferred tax liabilities (Net)	50	1,550.6	316.9
(d) Other non-current liabilities	24	4,999.4	5,828.2
Total non-current liabilities		13,725.1	15,211.2
(2) Current liabilities			
(a) Financial liabilities			
(i) Borrowings	25	39,443.6	61,978.8
(ii) Lease liabilities	54	1,256.9	1,280.8
(iii) Trade payables	74	56,533.0	56,815.2
(iv) Other financial liabilities	26	15,067.0	15,930.9
(b) Other current liabilities	27	10,844.6	6,427.2
(c) Provisions	28	53,575.6	53,543.8
(d) Current tax liabilities (Net)	29	4,117.0	3,087.1
Total current liabilities		169,837.7	199,063.8
Liabilities directly associated with assets classified as held for sale	3C	6.3	6.2
Total liabilities		194,569.1	214,281.2
TOTAL EQUITY AND LIABILITIES		865,628.8	807,435.9

The accompanying notes are an integral part of the financial statements.
As per our report of even date

For **N B S B C & CO LLP**
Chartered Accountants
ICAI Firm Registration No.: 326482E/E346863

per **POUL ALWARES**
Partner
Membership No.: 1054
Mumbai, May 22, 2024

ARUP PANDEY
Company Secretary and Compliance Officer

For and on behalf of the Board of Directors of
MOON PHARMACEUTICAL INDUSTRIES LIMITED

ARJUN VINOD
Chairman and Managing Director
(DIN: 00004459)

RAMESH JAIN
Whole-time Director
(DIN: 01762734)

RAHUL RAMESH
Chief Financial Officer
Mumbai, May 22, 2024

Statement of Profit and Loss

for the year ended March 31, 2024

₹ in Million

Particulars	Notes	Year ended March 31, 2024	Year ended March 31, 2023
(I) Revenue from operations	30	484,968.5	438,856.8
(II) Other income	31	13,541.9	6,345.2
(III) Total income (I+II)		498,510.4	445,202.0
(IV) Expenses			
Cost of materials consumed	32	69,043.3	77,775.7
Purchases of stock-in-trade		34,661.5	35,715.0
Changes in inventories of finished goods, stock-in-trade and work-in-progress	33	2,921.3	(6,869.1)
Employee benefits expense	34	94,290.6	82,960.3
Finance costs	35	2,384.7	1,720.0
Depreciation and amortisation expense	3 (A & B)	25,566.4	25,294.3
Other expenses	36	154,181.8	131,546.0
Net (gain) / loss on foreign currency transactions		(361.3)	1,261.0
Total expenses (IV)		382,688.3	349,403.2
(V) Profit before exceptional items and tax (III-IV)		115,822.1	95,798.8
(VI) Exceptional items	61	4,943.2	1,714.5
(VII) Profit before tax (V-VI)		110,878.9	94,084.3
(VIII) Tax expense/(credit)			
Current tax		19,893.0	18,692.2
Deferred tax		(5,498.5)	(10,216.3)
Total tax expense (VIII)	49	14,394.5	8,475.9
(IX) Profit for the year before share of profit/(loss) of associates and joint venture (VII-VIII)		96,484.4	85,608.4
(X) Share of profit/(loss) of associates (net of tax)		(382.7)	(476.7)
(XI) Share of profit/(loss) of joint venture (net of tax)		(1.4)	(2.3)
(XII) Profit for the year before non-controlling interests (IX+X+XI)		96,100.3	85,129.4
(XIII) Non-controlling interests	71	336.5	393.6
(XIV) Profit for the year of the parent company (XII-XIII)		95,763.8	84,735.8
Earnings per equity share (face value per equity share - ₹ 1)			
Basic		35.9	28.5
Diluted		35.9	28.5

The accompanying notes are an integral part of the financial statements.
As per our report of even date

For **N B S B C & CO LLP**
Chartered Accountants
ICAI Firm Registration No.: 326482E/E346863

per **POUL ALWARES**
Partner
Membership No.: 1054
Mumbai, May 22, 2024

ARUP PANDEY
Company Secretary and Compliance Officer

For and on behalf of the Board of Directors of
MOON PHARMACEUTICAL INDUSTRIES LIMITED

ARJUN VINOD
Chairman and Managing Director
(DIN: 00004459)

RAMESH JAIN
Whole-time Director
(DIN: 01762734)

RAHUL RAMESH
Chief Financial Officer
Mumbai, May 22, 2024

NOTE: 3E Intangible assets under development (R&D)

- Opening with investments of ₹60,098.1 million, we continued to prioritize R&D, ending the year at ₹64,461.5 million. This year's investment increase reflects our ongoing focus on sustaining our innovation pipeline.
- R&D costs are capitalized in accordance with standard accounting practices, reflecting our expectation of generating future economic benefits from these investments. Specific details on the projects and their expected outcomes remain confidential to maintain competitive advantage.